| 臺大學術典藏 |
2021-07-01T02:35:22Z |
Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE)
|
Talhouk A.;George J.;Wang C.;Budden T.;Tan T.Z.;Chiu D.S.;Kommoss S.;Leong H.S.;Chen S.;Intermaggio M.P.;Gilks B.;Nazeran T.M.;Volchek M.;Elatre W.;Bentley R.C.;Senz J.;Lum A.;Chow V.;Sudderuddin H.;Mackenzie R.;Leong S.C.Y.;Liu G.;Johnson D.;Chen B.;Alsop J.;Banerjee S.N.;Behrens S.;Bodelon C.;Brand A.H.;Brinton L.;Carney M.E.;Chiew Y.-E.;Cushing-Haugen K.L.;Cybulski C.;Ennis D.;Fereday S.;Fortner R.T.;Garc?A-Donas J.;Gentry-Maharaj A.;Glasspool R.;Goranova T.;Greene C.S.;Haluska P.;Harris H.R.;Hendley J.;Hernandez B.Y.;Herpel E.;Jimenez-Linan M.;Karpinskyj C.;Kaufmann S.H.;Keeney G.L.;Kennedy C.J.;Kobel M.;Koziak J.M.;Larson M.C.;Lester J.;Lewsley L.-A.;Lissowska J.;Lubi?Ski J.;Luk H.;Macintyre G.;Mahner S.;Mcneish I.A.;Menkiszak J.;Nevins N.;Osorio A.;Oszurek O.;Palacios J.;Hinsley S.;Pearce C.L.;Pike M.C.;Piskorz A.M.;Ray-Coquard I.;Rhenius V.;Rodriguez-Antona C.;Sharma R.;Sherman M.E.;De Silva D.;Singh N.;Sinn P.;Slamon D.;Song H.;Steed H.;Stronach E.A.;Thompson P.J.;To?Oczko A.;Trabert B.;Traficante N.;Tseng C.-C.;Widschwendter M.;Wilkens L.R.;Winham S.J.;Winterhoff B.;Beeghly-Fadiel A.;Benitez J.;Berchuck A.;Brenton J.D.;Brown R.;Chang-Claude J.;Chenevix-Trench G.;Defazio A.;Fasching P.A.;Garc?A M.J.;Gayther S.A.;Goodman M.T.;Gronwald J.;Henderson M.J.;Karlan B.Y.;Kelemen L.E.;Menon U.;Orsulic S.;Pharoah P.D.P.;Wentzensen N.;Wu A.H.;Schildkraut J.M.;Rossing M.A.;Konecny G.E.;Huntsman D.G.;Ruby Yun-Ju Huang;Goode E.L.;Ramus S.J.;Doherty J.A.;Bowtell D.D.;Anglesio M.S.;Aocs Group; Talhouk A.; George J.; Wang C.; Budden T.; Tan T.Z.; Chiu D.S.; Kommoss S.; Leong H.S.; Chen S.; Intermaggio M.P.; Gilks B.; Nazeran T.M.; Volchek M.; Elatre W.; Bentley R.C.; Senz J.; Lum A.; Chow V.; Sudderuddin H.; Mackenzie R.; Leong S.C.Y.; Liu G.; Johnson D.; Chen B.; Alsop J.; Banerjee S.N.; Behrens S.; Bodelon C.; Brand A.H.; Brinton L.; Carney M.E.; Chiew Y.-E.; Cushing-Haugen K.L.; Cybulski C.; Ennis D.; Fereday S.; Fortner R.T.; Garc?a-Donas J.; Gentry-Maharaj A.; Glasspool R.; Goranova T.; Greene C.S.; Haluska P.; Harris H.R.; Hendley J.; Hernandez B.Y.; Herpel E.; Jimenez-Linan M.; Karpinskyj C.; Kaufmann S.H.; Keeney G.L.; Kennedy C.J.; Kobel M.; Koziak J.M.; Larson M.C.; Lester J.; Lewsley L.-A.; Lissowska J.; Lubi?ski J.; Luk H.; Macintyre G.; Mahner S.; McNeish I.A.; Menkiszak J.; Nevins N.; Osorio A.; Oszurek O.; Palacios J.; Hinsley S.; Pearce C.L.; Pike M.C.; Piskorz A.M.; Ray-Coquard I.; Rhenius V.; Rodriguez-Antona C.; Sharma R.; Sherman M.E.; de Silva D.; Singh N.; Sinn P.; Slamon D.; Song H.; Steed H.; Stronach E.A.; Thompson P.J.; To?oczko A.; Trabert B.; Traficante N.; Tseng C.-C.; Widschwendter M.; Wilkens L.R.; Winham S.J.; Winterhoff B.; Beeghly-Fadiel A.; Benitez J.; Berchuck A.; Brenton J.D.; Brown R.; Chang-Claude J.; Chenevix-Trench G.; deFazio A.; Fasching P.A.; Garc?a M.J.; Gayther S.A.; Goodman M.T.; Gronwald J.; Henderson M.J.; Karlan B.Y.; Kelemen L.E.; Menon U.; Orsulic S.; Pharoah P.D.P.; Wentzensen N.; Wu A.H.; Schildkraut J.M.; Rossing M.A.; Konecny G.E.; Huntsman D.G.; RUBY YUN-JU HUANG; Goode E.L.; Ramus S.J.; Doherty J.A.; Bowtell D.D.; Anglesio M.S.; AOCS Group |
| 臺大學術典藏 |
2020-03-23T07:18:55Z |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Fresco R.; Helms H.-J.; Xu J.; Lin Y.G.; Sparano J.; Slamon D.; Beckmann M.W.; Afenjar K.; Campone M.; Boileau J.-F.; Wildiers H.; Stroyakovskiy D.; Harbeck N.; Valero V.; Thompson A.M.; CHIUN-SHENG HUANG; Jung K.H.; Symmans W.F.; Martin M.; Hurvitz S.A.; Hurvitz S.A.;Martin M.;Symmans W.F.;Jung K.H.;Chiun-Sheng Huang;Thompson A.M.;Harbeck N.;Valero V.;Stroyakovskiy D.;Wildiers H.;Campone M.;Boileau J.-F.;Beckmann M.W.;Afenjar K.;Fresco R.;Helms H.-J.;Xu J.;Lin Y.G.;Sparano J.;Slamon D. |
| 臺大學術典藏 |
2020-03-07T06:48:22Z |
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
|
Kuo K.-T.; TSUI-LIEN MAO; Jones S.; Veras E.; Ayhan A.; Wang T.-L.; Glas R.; Slamon D.; Velculescu V.E.; Kuman R.J.; Shih I.-M. |
| 臺大學術典藏 |
2020-03-07T06:48:20Z |
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma
|
Vogelstein B.; Kinzler K.W.; Velculescu V.E.; Papadopoulos N.; Roden R.; Glas R.; Slamon D.; Diaz Jr. L.A.; Nakayama K.; TSUI-LIEN MAO; Shih I.-M.; Wang T.-L.; Jones S.; Jones S.;Wang T.-L.;Shih I.-M.;Tsui-Lien Mao;Nakayama K.;Roden R.;Glas R.;Slamon D.;Diaz Jr. L.A.;Vogelstein B.;Kinzler K.W.;Velculescu V.E.;Papadopoulos N. |
| 臺大學術典藏 |
2020-03-07T06:42:19Z |
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
|
KUAN-TING KUO; Mao T.-L.; Jones S.; Veras E.; Ayhan A.; Wang T.-L.; Glas R.; Slamon D.; Velculescu V.E.; Kuman R.J.; Shih I.-M. |
| 臺大學術典藏 |
2020-03-05T12:32:54Z |
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
|
Kuo K.-T.; TSUI-LIEN MAO; Jones S.; Veras E.; Ayhan A.; Wang T.-L.; Glas R.; Slamon D.; Velculescu V.E.; Kuman R.J.; Shih I.-M. |
| 臺大學術典藏 |
2020-03-05T12:32:53Z |
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma
|
Jones S.; Wang T.-L.; Shih I.-M.; TSUI-LIEN MAO; Nakayama K.; Roden R.; Glas R.; Slamon D.; Diaz Jr. L.A.; Vogelstein B.; Kinzler K.W.; Velculescu V.E.; Papadopoulos N. |
| 臺大學術典藏 |
2019 |
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study
|
Slamon D.; Thompson A.M.; Fraser Symmans W.; Hurvitz S.A.;Martin M.;Jung K.H.;Chiun-Sheng Huang;Harbeck N.;Valero V.;Stroyakovskiy D.;Wildiers H.;Campone M.;Boileau J.-F.;Fasching P.A.;Afenjar K.;Spera G.;Lopez-Valverde V.;Song C.;Trask P.;Boulet T.;Sparano J.A.;Fraser Symmans W.;Thompson A.M.;Slamon D.; Hurvitz S.A.; Martin M.; Jung K.H.; CHIUN-SHENG HUANG; Harbeck N.; Valero V.; Stroyakovskiy D.; Wildiers H.; Campone M.; Boileau J.-F.; Fasching P.A.; Afenjar K.; Spera G.; Lopez-Valverde V.; Sparano J.A.; Boulet T.; Trask P.; Song C. |
| 臺大學術典藏 |
2018-09-10T18:05:39Z |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Martin, M.; Symmans, W.F.; Jung, K.H.; Huang, C.-S.; Thompson, A.M.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.-F.; Beckmann, M.W.; Afenjar, K.; Fresco, R.; Helms, H.-J.; Xu, J.; Lin, Y.G.; Sparano, J.; Slamon, D.; Hurvitz, S.A.; CHIUN-SHENG HUANGet al. |
| 國立臺灣大學 |
2016 |
Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2-breast cancer (BC)
|
Hurvitz, S.; Abad, M. F.; Rostorfer, R.; Chan, D.; Egle, D.; Huang, C-S.; Barriga, S.; Costigan, T. M.; Caldwell, C. W.; Schilder, J. M.; Press, M. F.; Slamon, D.; Martin, M.; 黃俊升 |
| 臺大學術典藏 |
2009 |
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
|
KUAN-TING KUO; Mao T.-L.; Jones S.; Veras E.; Ayhan A.; Wang T.-L.; Glas R.; Slamon D.; Velculescu V.E.; Kuman R.J.; Shih I.-M. |
